Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach using anti-TNF agents in seropositive RA patients with Sjogren's overlap (positive SSA antibodies)?
Are you concerned about increased incidence of lymphoma?
Related Questions
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
How you do approach management of a patient with previously well-controlled RA, who is now having recurrent flares of multiple joints which is resistant to even high dose steroids?
How do you approach the timing of DMARD initiation in patients with active RA who are on treatment for latent TB?
How would you approach rheumatoid arthritis treatment for widespread large rheumatoid nodules but no active synovitis or subjective joint pain?
How do you approach methotrexate management around vaccines other than COVID and influenza?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Do you consider Anti-carbamylated protein antibodies (anti-CarP) as having any significance in evaluation of patients if RF and ACPA negative and clinically no active synovitis yet widespread arthralgias and generalized osteoarthritis?